Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David
  • Malinverni, Roberto
  • Carrillo-Reixach, Juan
  • Meers, Oliver
  • Garcia-Jaraquemada, Arce
  • Le Pannérer, Marguerite-Marie, 1990-
  • Valero, Vanesa
  • Pérez, Ainhoa
  • Del Río-Álvarez, Álvaro
  • Royo, Laura
  • Pérez-González, Beatriz
  • Raurell Vila, Helena
  • Acemel, Rafael D.
  • Santos-Pereira, José M.
  • Gómez Skarmeta, José Luis
  • Pasquali, Lorenzo
  • Manyé, Josep
  • Armengol, Carolina
  • Buschbeck, Marcus
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment., This research project was supported by the national grants RTI2018-094005-B-I00 and BFU2015-66559-P from FEDER / Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación (to M.B.); PI09/00751 , PI10/02082 , and PI13/02340 from the Instituto de Salud Carlos III (to C.A.); the MECD fellowship FPU14/06542 (to D.C.); AGAUR 2019 FI_B01024 and 2022 FI_B00528 fellowships (to J.C.-R. and A.D.R.-A., respectively); and predoctoral fellowships BES-2016-077251 (to M.-M.L.P.) and PRE2019-088529 (to O.M.). Research in the M.B. lab is further supported by the following grants: the Marie Skłodowska Curie Training network “ INTERCEPT-MDS ” H2020-MSCA-ITN-2020-953407 (to M.B.); MINECO-ISCIII PIE16/00011 (to M.B.); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to M.B.); AGAUR 2017-SGR-305 (to M.B.); and Fundació La Marató de TV3 257/C/2019 (to M.B.). C.A.’s research has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement nos. 668596 ( ChiLTERN ) and 826121 ( iPC ) as well as from CIBERehd ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). C.A. was supported by Ramón y Cajal ( RYC-2010-07249 ) of the Ministry of Science and Innovation of Spain. Research at the IJC is supported by the “ La Caixa” Foundation , the Fundació Internacional Josep Carreras , Celgene Spain , and the CERCA Programme / Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David
  • Malinverni, Roberto
  • Carrillo-Reixach, Juan
  • Meers, Oliver
  • Garcia-Jaraquemada, Arce
  • Pannérer, Marguerite-Marie Le
  • Valero, Vanesa
  • Pérez, Ainhoa
  • Río-Álvarez, Álvaro Del
  • Royo, Laura
  • Pérez-González, Beatriz
  • Raurell, Helena
  • Acemel, Rafael D.
  • Santos-Pereira, José M.
  • Garrido-Pontnou, Marta
  • Gómez-Skarmeta, José Luis
  • Pasquali, Lorenzo
  • Manyé, Josep
  • Armengol, Carolina
  • Buschbeck, Marcus
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment., This research project was supported by the national grants RTI2018-094005-B-I00 and BFU2015-66559-P from FEDER/Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación (to M.B.); PI09/00751, PI10/02082, and PI13/02340 from the Instituto de Salud Carlos III (to C.A.); the MECD fellowship FPU14/06542 (to D.C.); AGAUR 2019 FI_B01024 and 2022 FI_B00528 fellowships (to J.C.-R. and A.D.R.-A., respectively); and predoctoral fellowships BES-2016-077251 (to M.-M.L.P.) and PRE2019-088529 (to O.M.). Research in the M.B. lab is further supported by the following grants: the Marie Skłodowska Curie Training network “INTERCEPT-MDS” H2020-MSCA-ITN-2020-953407 (to M.B.); MINECO-ISCIII PIE16/00011 (to M.B.); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to M.B.); AGAUR 2017-SGR-305 (to M.B.); and Fundació La Marató de TV3 257/C/2019 (to M.B.). C.A.’s research has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement nos. 668596 (ChiLTERN) and 826121 (iPC) as well as from CIBERehd (CB06/04/0033) and AGAUR (2017-SGR-490). C.A. was supported by Ramón y Cajal (RYC-2010-07249) of the Ministry of Science and Innovation of Spain. Research at the IJC is supported by the “La Caixa” Foundation, the Fundació Internacional Josep Carreras, Celgene Spain, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David
  • Malinverni, Roberto
  • Carrillo-Reixach, Juan
  • Meers, Oliver
  • Garcia-Jaraquemada, Arce
  • Le Pannérer, Marguerite-Marie, 1990-
  • Valero, Vanesa
  • Pérez, Ainhoa
  • Del Río-Álvarez, Álvaro
  • Royo, Laura
  • Pérez-González, Beatriz
  • Raurell Vila, Helena
  • Acemel, Rafael D.
  • Santos-Pereira, José M.
  • Gómez Skarmeta, José Luis
  • Pasquali, Lorenzo
  • Manyé, Josep
  • Armengol, Carolina
  • Buschbeck, Marcus
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment., This research project was supported by the national grants RTI2018-094005-B-I00 and BFU2015-66559-P from FEDER / Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación (to M.B.); PI09/00751 , PI10/02082 , and PI13/02340 from the Instituto de Salud Carlos III (to C.A.); the MECD fellowship FPU14/06542 (to D.C.); AGAUR 2019 FI_B01024 and 2022 FI_B00528 fellowships (to J.C.-R. and A.D.R.-A., respectively); and predoctoral fellowships BES-2016-077251 (to M.-M.L.P.) and PRE2019-088529 (to O.M.). Research in the M.B. lab is further supported by the following grants: the Marie Skłodowska Curie Training network “ INTERCEPT-MDS ” H2020-MSCA-ITN-2020-953407 (to M.B.); MINECO-ISCIII PIE16/00011 (to M.B.); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to M.B.); AGAUR 2017-SGR-305 (to M.B.); and Fundació La Marató de TV3 257/C/2019 (to M.B.). C.A.’s research has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement nos. 668596 ( ChiLTERN ) and 826121 ( iPC ) as well as from CIBERehd ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). C.A. was supported by Ramón y Cajal ( RYC-2010-07249 ) of the Ministry of Science and Innovation of Spain. Research at the IJC is supported by the “ La Caixa” Foundation , the Fundació Internacional Josep Carreras , Celgene Spain , and the CERCA Programme / Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David|||0000-0001-7930-0935
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Meers, Oliver|||0000-0001-9532-7767
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Valero, Vanesa
  • Pérez, Ainoha
  • Del Río-Álvarez, Álvaro|||0000-0003-2338-0782
  • Royo, Laura|||0000-0001-5770-2001
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Acemel, Rafael D.|||0000-0003-4120-0140
  • Santos-Pereira, José M.|||0000-0003-3949-0644
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Gómez-Skarmeta, José Luís|||0000-0001-5125-4332
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Manyé, Josep|||0000-0002-3121-8016
  • Armengol, Carolina|||0000-0002-4690-4027
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment.